KE
CLDX icon

KLP Enterprises’s Celldex Therapeutics CLDX Stock Holding History

KLP Enterprises’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-457,667
Closed -$1.36M – 1
2018
Q4 		$1.36M Hold
457,667
– – 100% 1
2018
Q3 		$3.1M Hold
457,667
– – 100% 1
2018
Q2 		$3.46M Hold
457,667
– – 100% 1
2018
Q1 		$16M Hold
457,667
– – 100% 1
2017
Q4 		$19.5M Hold
457,667
– – 100% 1
2017
Q3 		$19.6M Hold
457,667
– – 100% 1
2017
Q2 		$17M Hold
457,667
– – 100% 1
2017
Q1 		$24.8M Hold
457,667
– – 100% 1
2016
Q4 		$24.3M Buy
+457,667
New +$26M 100% 1

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

KLP Enterprises's CLDX Position: Q1 2019 in Review

KLP Enterprises sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 457,667 shares — an estimated $1.36M sold.

KLP Enterprises first reported a position in CLDX in Q4 2016 and held it in 9 quarters. The position peaked at $24.8M in Q1 2017. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • KLP Enterprises reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • KLP Enterprises sold 457,667 Celldex Therapeutics shares in Q1 2019, an estimated $1.36M.
  • KLP Enterprises first reported a position in Celldex Therapeutics in Q4 2016 and held it in 9 quarters.
  • KLP Enterprises's Celldex Therapeutics position peaked at $24.8M in Q1 2017.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on KLP Enterprises's 13F filing for Q1 2019.